Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-Lung-713 in EGFR-mutated non-squamous NSCLC after progression on third-generation EGFR TKI
2025-521124-29-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Objective response and Progression-free survival. Planned start Feb 2026; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521124-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521124-29-00.